Acelrx Pharmaceuticals Inc Book/Share
What is the Book/Share of Acelrx Pharmaceuticals Inc?
The Book/Share of Acelrx Pharmaceuticals Inc is 0.08
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on NASDAQ compared to Acelrx Pharmaceuticals Inc
What does Acelrx Pharmaceuticals Inc do?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Companies with book/share similar to Acelrx Pharmaceuticals Inc
- Stampede Capital has Book/Share of 0.08
- Twintek Investment has Book/Share of 0.08
- Alloy Resources has Book/Share of 0.08
- New Oroperu Resources has Book/Share of 0.08
- Spartan Acquisition has Book/Share of 0.08
- Labrador Gold has Book/Share of 0.08
- Acelrx Pharmaceuticals Inc has Book/Share of 0.08
- American Rare Earths has Book/Share of 0.08
- 5G Networks has Book/Share of 0.08
- Visioneering Technologies has Book/Share of 0.08
- Loco Hong Kong has Book/Share of 0.08
- Four Arrows Capital has Book/Share of 0.08
- Sintana has Book/Share of 0.08